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Abstract
Considering the high clinical and forensic relevance of pharmaco-adherence during lisdex-
amphetamine (LDX) treatment for attention-deficit/hyperactivity disorder (ADHD), the aim
here was to evaluate hair analysis as a tool for monitoring compliance in patients currently
undergoing long term treatment with LDX, by detecting possible interruptions of medication
intake or changes in dosage. For this purpose, a total of 24 patients from an outpatient clinic
for ADHD were recruited. Hair and urine samples were taken after three consecutive ther-
apy sessions over a 7-month period and analyzed for amphetamine (AMP) enantiomers
and other drugs, using chiral and achiral liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Participants also provided information on the condition of their hair, the con-
sumption of illegal psychotropic substances and the regularity of taking LDX. Two partici-
pants withdrew from the study early. Urine analyses were positive for D-AMP in all urine
samples and therapy sessions, except in two patients who did not take LDX on a daily basis.
D-AMP was detected in all hair samples; however, no correlation was found between pre-
scribed dose/day and D-AMP concentrations in proximal hair segments. Qualitative inter-
pretation of hair analysis showed that 18 of the 22 study completers were compliant
concerning the intake of LDX without additional consumption of illegal D,L-AMP. Analysis of
urine taken during the therapy sessions showed no correlation between D-AMP concentra-
tions and prescribed dosage, with or without normalization for creatinine. In conclusion, chi-
ral LC-MS/MS hair analysis might represent a non-invasive way to confirm LDX use within
the approximate period covered by the hair segment tested, but it does not allow for quanti-
tative therapeutic drug monitoring because of interindividual variability of concentrations in
hair. Drug concentrations in hair at different stages of long-term treatment should thus be
interpreted with caution by clinicians and forensic experts alike when making assessments
of treatment adherence.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobiological disorder pre-
dominantly manifesting itself in childhood and persisting into adulthood in an estimated two-
thirds of cases [1]. Despite the evidence supporting stimulant treatment and the knowledge of
worse outcomes across domains without treatment, many patients remain skeptical of long-
term medication use, leading to concerns about adherence. Adherence is commonly defined
as a combination of persistence (i.e., whether an individual continues to refill prescriptions in
line with the recommended duration of therapy) and compliance (whether an individual actu-
ally takes doses according to the issued prescription) [2, 3]. In a literature review, Adler and
Nierenberg found that among children and adults, 13% to 64% discontinued their treatment
[4]. Understanding the reasons for undertreatment as well as evaluating pharmacological treat-
ment adherence is thus of high clinical, and, as will be seen later, forensic relevance. Stimulants
like methylphenidate (MPH) and amphetamine (AMP) are the most commonly prescribed
pharmacological treatments for ADHD [5]. In 2007, another pharmaceutical, lisdexampheta-
mine (LDX) (Vyvanse1), became available for treatment, starting in the United States. LDX is
an inactive prodrug of D-AMP in which D-AMP is bound by an amide bond to the amino
acid L-lysine. Because of the slow and continuous release of D-AMP, the potential for abuse is
believed to be lower than that for the immediately active D-AMP and 3:1 D:L-AMP com-
pounds [6–8]. In Switzerland LDX (Elvanse1) is approved as a treatment for ADHD in chil-
dren from 6 years of age, adolescents and—since 2014—also for adults up to 55 years of age
who show insufficient response to MPH treatment, thus serving as a second-line treatment
[9].
As with all chronic disorders, adherence to treatment for ADHD appears to be a key condi-
tion for a successful clinical outcome, i.e., the improvement of cognitive/social functioning
and quality of life. In addition, the question of pharmaco-adherence can also arise in a forensic
context: for example, in social security law the question of receiving benefits, and, in criminal
law, the legal prognosis may be tied to adherence to treatment for ADHD [10]. Indirect meth-
ods for evaluating persistence, such as counting tablets, monitoring the filling of prescriptions,
self-report diaries or reports from relatives are subject to uncertainty [11, 12]. In contrast, mea-
suring the concentration of the active substance or its metabolites in blood, urine or saliva
allows for a more direct evaluation of compliance [13]. However, these measurements usually
only provide an indication of compliance, depending on the drug’s pharmacological half-life
over several hours to days before the sample was taken, resulting in a “snapshot” rather than a
long-term evaluation. By contrast, hair analysis allows for more complete documentation over
an extended time period, depending on hair length.
Hair growth rate on the head averages 1 cm per month. It takes about 10–14 days, until the
newly grown hair reaches the surface of the scalp and can then be cut; thus, in theory, a 5–6
cm sample would permit the evaluation of medication compliance over about 6 months [14].
The same would be true for 2 cm proximal hair segments taken at three time points with inter-
vals of two months. Plasma and urine concentration of AMP after administration of one or
several doses of LDX have been studied in previous pharmacokinetic studies [15–19]. The con-
centration of AMP in saliva after a single dose of LDX has also been documented [20]. Hair
analysis was previously applied to compliance monitoring by Binz et al. after low dose applica-
tion of 30 to 80 mg/day for 9 patients in long term therapy with LDX, and high inter-individual
variations in D-AMP concentrations were found [21]. Prior to introducing chiral AMP testing
to evaluate compliance and long-term therapy adherence in LDX-patients, it is therefore para-
mount to gather reliable individual baseline values of AMP-concentration in hair after regular
intake of LDX. Changes in compliance with LDX pharmacotherapy might then be detectable
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during long-term treatment over several months by changes in D-AMP concentrations in
proximal hair segments taken at different time-points.
The primary aim of this study was therefore to evaluate hair analysis as a means of monitor-
ing compliance in patients currently undergoing long-term treatment with Elvanse1, i.e. to
detect possible interruptions of medication intake or changes in dosage. It was hoped that chi-
ral AMP-testing could be used in the future to evaluate compliance and that, by integrating
data on persistence, a more robust understanding of adherence among ADHD-patients taking
LDX could be developed. Since a correlation between LDX drug dosage and its concentration
in hair was recently suggested, we furthermore aimed to gather more data on this subject in a
larger cohort, reflecting clinical reality [21].
The results of this project should not only be of potentially great importance to clinicians
evaluating adherence to pharmacological treatment interventions in cases of perceived treat-
ment failure, but also help patients to prove treatment compliance in various forensic contexts,
such as for social insurance agencies as part of their obligation to cooperate if receiving a dis-
ability pension. The study is also designed to help establish forensic certainty between mem-
bers of the police force and patients receiving LDX during traffic checks, since it should make
it possible to differentiate between legal and illegal AMP consumption.
Materials and methods
Compliance with ethical standards
This study was approved by the Cantonal Ethics Committees of Zurich and Bern (project ID
2017–00783). Written informed consent was obtained from all participants. Participants
received no compensation for their participation. All procedures performed were in accor-
dance with the ethical standards of the institutional research committee and the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Study participants
Individuals were recruited among patients undergoing treatment at the ADHD outpatient
clinic of the Psychiatric University Hospital Zurich. Recruitment took place during the regular
therapy sessions as well as by phone and postal mail. Inclusion criteria were clinically diag-
nosed ADHD, treatment with Elvanse1 for at least 1 month, age� 18 years, and head-hair
length� 1 cm. Exclusion criteria included insufficient knowledge of German and lack of intel-
lectual understanding of the project. Treatment discontinuation with Elvanse1, revocation of
consent, and impairment of the patient-psychiatrist-relationship (subjective feeling of the
patient and/or the treating psychiatrist) were criteria for an early termination of the study.
Study design and sample collection
The study was carried out within the framework of the regular treatment at the ADHD outpa-
tient clinic of the Psychiatric University Hospital Zurich, which includes bimonthly to quar-
terly therapy sessions. Urine and hair samples were obtained during three consecutive therapy
sessions. Urine samples were collected in 3.5 mL tubes containing 4 mg of sodium azide as a
bacteriostatic preservative (Greiner Bio-One, Kremsmünster, Austria) and were stored at
-20˚C until analysis. Collection of urine specimens did not occur under observation. Sample
adulteration (e.g. dilution, chemical manipulation, substitution) seemed unlikely since urine
samples were provided voluntarily and the analytical findings had no consequences for the
participants. Locks of hair were cut from the posterior vertex region of the patients’ heads,
close to the scalp. The samples were wrapped in aluminum foil and stored at room
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temperature until analysis. Personal and persistence data and was obtained from the patients’
medical records and by oral questioning during the therapy sessions. If patients did not show
up for one or more months after their scheduled appointment and/or if they did not renew
their prescription, it was considered as treatment discontinuation, which is in line with previ-
ous research on treatment adherence [22, 23].
Samples and data were anonymized and sent to the Institute of Forensic Medicine at the
University of Bern for analysis. D- and L-AMP concentrations in urine and hair were deter-
mined by a chiral liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
[24]. Since methamphetamine (MAMP) is metabolized to AMP [25], positive AMP findings in
biological specimens can be the result of MAMP consumption. For this reason, hair samples
were also analyzed by a well-established LC-MS/MS method for the achiral determination of
MAMP and other basic drugs. Findings that might affect the trust between patients and psy-
chiatrists were not reported to the treating psychiatrist and are not presented in this paper (i.e.
indications of the abuse of illegal drugs other than that self-reported by the patient).
Chemicals and reagents
Standards and deuterated internal standards were purchased from Cerilliant (Round Rock,
TX, USA). Working solutions for preparing calibration samples for urine and hair analysis
were obtained via serial dilution of the standard solution in acetonitrile. Acetonitrile (99.9%,
HPLC gradient grade) was acquired from Acros Organics (Chemie Brunschwig, Basel, Swit-
zerland). Ammonium hydroxide solution (25%), methanol, dichloromethane (all EMSURE1),
and acetone (LiChrosolv1) were obtained from Merck (Grogg Chemie, Stettlen, Switzerland).
Formic acid solution (puriss p.a., 50% in water) and ammonium formate (LiChropur1) were
from Sigma-Aldrich (Buchs, Switzerland). Ultrapure water was generated in-house with a
Direct-Q water purification system from Millipore (Zug, Switzerland). Drug-free urine and
hair samples were donated by employees of the authors’ institute. Urine creatinine concentra-
tions were determined spectrophotometrically on an AU480 analyzer (Beckman Coulter,
Nyon, Switzerland) using the Jaffe method [26].
Preparation of urine samples
Preparation of urine samples for chiral LC-MS/MS analysis was carried out according to a
previously published procedure [27]. Briefly, 75 μL of urine sample were thoroughly mixed
with 15 μL of internal standard solution (10 mg/L D,L-AMP-d5) and 1.41 mL of water. The
racemic D,L-AMP-d5 consists of a 1:1 ratio of D-AMP-d5 and L-AMP-d5 and is baseline sepa-
rated by chiral analysis [28]. Calibration samples were prepared by spiking 5 μL of standard
working solution into 70 μL of blank urine. Calibration levels were 0.05, 0.1, 0.5, 1, 5, 10, and
25 mg/L per AMP enantiomer, with the lowest calibrator being the lower limit of quantifica-
tion (LLOQ).
Preparation of hair samples
In general, the proximal 0–2 cm segment of each collected hair-lock was used for analysis. To
remove external contaminations, the hair segments were placed in glass tubes and shaken for 4
min with water, followed by subsequent washing steps with acetone and dichloromethane
(with 4 mL each). After drying at room temperature, the proximal hair sample segments were
cut with scissors into small pieces and aliquots of 30 mg were weighed into polypropylene
tubes. Calibration samples were prepared by spiking 30 μL of standard working solution into
30 mg of finely cut blank hair. For extraction, 10 μL of internal standard solution—containing
racemic D,L-AMP-d5 besides deuterated analogues of other drugs (see below for ’achiral
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LC-MS/MS analysis’) including MAMP—and 1 mL of methanol were added to the samples.
After brief vortex mixing, the samples were incubated in an ultrasonic water bath for 3 h. Sub-
sequently, the samples were centrifuged at 17’000 g and 8 ˚C for 10 min using a Mikro 220R
benchtop centrifuge from Hettich (Bäch, Switzerland). For the chiral LC-MS/MS analysis of
AMP, the supernatants were directly transferred to autosampler vials. For the achiral LC-MS/
MS analysis of AMP, MAMP and other drugs, the supernatants were diluted 10-fold with a
water/acetonitrile/formic acid solution (97.5/2.5/0.1, v/v/v) containing 5 mM ammonium for-
mate. Calibration levels were 50, 125, 250, 1250, and 2500 pg/mg per AMP enantiomer (chiral
analysis) and 100, 250, 500, 2500, and 5000 pg/mg for each analyte (achiral analysis), respec-
tively (the lowest calibrator being the LLOQ).
Achiral LC-MS/MS analysis
Basic drugs and their metabolites (AMP, MAMP, 3,4-methylenedioxymethamphetamine
(MDMA), 3,4-methylenedioxyamphetamine (MDA), morphine, 6-acetyl-morphine, codeine,
dihydrocodeine, cocaine, benzoylecgonine, cocaethylene, methadone/EDDP, MPH) were
determined in hair by a validated achiral LC-MS/MS method. This method comprises chro-
matographic separation of the analytes on a Kinetex 2.6 μm F5 column (150 x 2.1 mm, Phe-
nomenex, Torrance, CA, USA) using gradient elution with water/acetonitrile containing 0.1%
formic acid, followed by tandem-mass spectrometric detection with a 5500 QTRAP1 hybrid
triple quadrupole/linear ion trap mass spectrometer and a Turbo V ion source (SCIEX, Brugg,
Switzerland) operated in positive ESI and SRM mode. Data were acquired and analyzed with
Analyst software version 1.6.2 (SCIEX, Brugg, Switzerland). For all analytes that were quantita-
tively determined, linearity ranges are from 100–5000 pg/mg and the LLOQ is 100 pg/mg.
This method has been validated and is used in the accredited laboratory. Further details of this
method can be obtained from the authors on request.
Chiral LC-MS/MS analysis
D- and L-AMP concentrations in urine were determined with a recently developed and vali-
dated column-switching LC-MS/MS method [27]. For the analysis of hair samples, the method
was slightly adapted and validated according to international guidelines on bioanalytical
method validation [29, 30]. Linearity, LLOQ, intra- and inter-batch accuracy and imprecision,
selectivity, recovery, matrix effect, process efficiency, carry-over, and re-injection reproduc-
ibility were evaluated. Further details of validation data are provided in the S1 File. An aliquot
of the diluted urine sample (1 μL) and the hair extract (5 μL), respectively, was directly
injected. The liquid chromatography (LC) equipment consisted of an UltiMate 3000 HPLC
system (Dionex, Olten, Switzerland) equipped with two binary pumps, an isocratic pump, a
thermostatted column compartment equipped with a built-in 6-port switching valve, and a
thermostatted plate autosampler. LC was performed with a Gemini 5 μm C18 110 Å trapping
column (10 x 2.0 mm) and a Lux 3 μm AMP analytical column (150 x 3.0 mm) combined with
a KrudKatcher Ultra in-line filter, all obtained from Phenomenex (CA, USA). Mobile phase A
was 0.1 M aqueous ammonia (pH 11), which was freshly prepared on each day of analysis, and
mobile phase B was acetonitrile. The autosampler and column oven were maintained at 8 and
30 ˚C, respectively. A 5 μL aliquot of the methanolic hair extract was loaded onto the achiral
C18 trapping column with a 400 μL/min flow of 20% B delivered by binary pump 1. To
enhance the loading and trapping step efficiencies, the injection solution was diluted via a T-
union with a 200 μL/min flow of mobile phase A delivered by the isocratic pump. After 1 min,
the valve was switched and the trapping column was connected to a chiral analytical column in
backflush direction. Elution of the enriched and cleaned analytes from the trapping to the
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analytical column was performed under isocratic conditions with a 500 μL/min flow of 25% B
delivered by binary pump 2. During the elution, the flows of binary pump 1 and the isocratic
pump were reduced to 20 μL/min since they were diverted into the waste. After 13 min, the
valve was switched back to the loading position and the flow rates of the isocratic and binary
pump 1 were increased to their initial values. Total run time was 16 min.
Mass spectrometric data were collected in positive electrospray ionization (ESI) and
selected reaction monitoring (SRM) mode with a 5500 QTRAP1 hybrid triple quadrupole/lin-
ear ion trap mass spectrometer. Optimized SRM settings were determined by direct infusion
of D,L-AMP and D,/L-AMP-d5 via syringe pump and are specified in Table 1.
For data analysis, peak area ratios of analyte to internal standard were calculated for each
analyte concentration (x) and linear least-squares regression with a 1/x weighting factor was
employed to construct daily calibration curves. Creatinine-normalized urinary AMP concen-
trations (mg/L) were calculated by dividing AMP concentration (mg/L) by creatinine concen-
tration (mg/dL) and multiplying by a creatinine reference concentration of 100 mg/dL [31].
GraphPad Prism 6.05 software for Windows (GraphPad Software, La Jolla, CA, USA) and
Microsoft Excel 2010 were used for data analysis and visualization.
Linear ranges in urine and hair were 0.05 to 25 mg/L and 50–2500 pg/mg, respectively, for
both AMP enantiomers. LLOQs for urine and hair were 0.05 mg/L and 50 pg/mg, respectively.
Chromatograms of chiral hair analysis are depicted in Fig 1.
Statistical data evaluation
For testing data sets for correlation between daily Elvanse1 dose and D-AMP hair concentra-
tions Microsoft Excel 2010 was used.
Results
Participants
Seven men and 17 women participated in the study. Of these, 23 were of European descent
and one was Asian. Participants’ characteristics are detailed in Table 2. Participants varied in
Table 1. Optimized tandem mass spectrometric parameters for the analysis of AMP enantiomers in hair.
Analyte Q1 mass (m/z) Q3 mass (m/z)a Dwell time (ms) DP (V) EP (V) CE (eV) CXP (V)
L-AMP 136.1 91.0 150 45 10 26 8
136.1 119.0 150 45 10 11 8
D-AMP 136.1 91.0 150 45 10 26 8
136.1 119.0 150 45 10 11 8
AMP-d5 141.1 93.0 150 45 10 26 8
Optimized source settings
Ion spray voltage 3.5 kV





Q1 quadrupole 1, Q3 quadrupole 3, DP declustering potential, EP entrance potential, CE collision energy, CXP cell exit potential.
aBold: m/z values of ions used for quantification.
b Arbitrary units for the gas settings.
https://doi.org/10.1371/journal.pone.0248747.t001
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age (24–59 years) and in body mass index (> 30.0, obese: n = 2; 25.0–29.9, overweight: n = 4;
18.5–24.9, normal: n = 18). Six individuals received Elvanse1 in combination with MPH
(n = 5) or D-AMP sulfate (n = 1, 5–10 mg/day). Several participants received concomitant
medication for other mental health conditions. Seven participants self-reported use of illegal
Fig 1. SRM ion chromatograms of (A) blank hair, (B) analytes at the lower limit of quantification (50 pg/mg per
AMP enantiomer), and (C) an authentic hair sample from a patient treated with Elvanse1. Blue: AMP SRM1 (m/z
136.1! 91.0); Red: AMP SRM2 (m/z 136.1! 119.0); Green: AMP-d5 SRM1 (m/z 141.0! 93.0). Peaks are annotated
with retention times: Pane A: 10.04 min: L-AMP-d5; 11.00 min: D-AMP-d5. Pane B: 10.23 min: L-AMP; 11.14 min:
D-AMP. Pane C: 11.21 min: D-AMP.
https://doi.org/10.1371/journal.pone.0248747.g001
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Table 2. Participants’ characteristics, diagnosis, treatment, and self-reported drug abuse.














1 E m 26 33.7 F90.0 F32.1 3 50 escitalopram nicotine
2 E f 55 27.5 F90.0 F32.1 16 50 sertraline -
3 E f 27 23.0 F90.0 20 60 - -
4 E m 26 23.4 F90.0 1 40 / 90 quetiapine / duloxetine cannabis
5 E m 37 21.9 F90.0 20 320 - -
6 E m 49 21.6 F90.0 F10.2
F14
32 70 - cocaine, nicotine
7 E m 24 20.8 F90.0 F17.2 16 30 / 50 - AMP, nicotine,
cannabis
8 E f 27 20.7 F90.0 32 40 - -
9 E f 35 25.7 F90.0 F17.2 20 50 - nicotine
10 E f 46 20.4 F90.0 14 30 - -
11 E m 34 23.4 F90.0 27 30 - -
12 E f 52 41.5 F90.0 F50.9 33 30 MPH -
13 E f 45 19.6 F90.0 34 30–50f MPH MDMA
14 A f 45 20.2 F90.0 13 30 / 40 / 70 venlafaxine -
15 E f 24 20.8 F90.0 6 60 - cannabis
16 E f 38 26.1 F90.0 E06.3
L93
17 50 MPH -
17 E f 42 22.0 F90.0 F33 3 20 or 30g sertraline nicotine
18 E f 43 21.0 F90.0 F50.2 1 30 / 60 fluoxetine -
19 E m 41 29.4 F90.0 F12.1 13 100 - AMP
20 E f 59 23.5 F 90.0 26 50 MPH -
21 E f 34 19.0 F90.0 F12.2 24 100 D-AMP sulfate (5–10
mg/day)
cannabis, nicotine
22 E f 34 20.3 F90.0 37 80 - -
23 E f 45 22.0 F90.0 2 40 MPH -




Median 37.5 21.9 18.5
Mean 38.3 23.9 18.5
SD 10.3 5.3 11.3
All (1–24)
Median 39.5 22.0 18.5
Mean 39.0 23.8 18.7
SD 10.1 5.1 12.0
aE, European; A, Asian.
b Age at the time of the first sample collection.
c ICD-10, International Classification of Diseases, 10th revision.
d Duration of Elvanse1 treatment prior to the first sample collection.
e Slashes indicate that the prescribed Elvanse1 dose changed during the study.
f Participant takes variable doses of Elvanse1, but not on a daily basis.
g Participant takes alternating doses of Elvanse1.
https://doi.org/10.1371/journal.pone.0248747.t002
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drugs (cannabis (n = 4), cocaine (n = 1), AMP (n = 2), MDMA (“ecstasy”, n = 1)). Two partici-
pants withdrew from the study early (due to treatment discontinuation with Elvanse1 and for
personal reasons, respectively).
Urine analysis
Creatinine-normalized urinary D-AMP concentrations measured in study completers are pre-
sented in Table 3. Creatinine is a by-product of muscle metabolism. It is normally excreted
into urine at a constant rate and its level in the urine reflects the urine concentration. Normal-
izing urinary drug concentrations to a constant creatinine concentration is useful to account
for intra- and interpersonal differences in urine dilution (e.g. caused by excessive or reduced
fluid intake) [31, 32]. All but participants 13 and 15 tested positive for D-AMP at all three time
points. The absence of D-AMP in the urine samples of participant 13 is not too surprising
since this participant reported to the treating psychiatrist that she hadn’t been taking Elvanse1
on a daily basis. The absence of D-AMP in the second and third urine sample of participant 15
may indicate non-compliance with the prescribed Elvanse1 regimen, but could also be due to
inappropriate timing of urine collection relative to Elvanse1 intake. In our study, time inter-
vals between last Elvanse1 intake and urine collection in our study were not controlled and
ranged approximately from 0.5 h– 30 h. D-AMP concentrations, even after creatinine-normal-
ization, displayed high intra- and intersubject variability. No correlation between prescribed
Elvanse1 dose and D-AMP concentration was observed. Participants 6 and 7 tested positive
for L-AMP at one and two time points, respectively. Participant 7 self-reported abuse of illegal
racemic AMP. Measured L-AMP concentrations were approximately 10–100 times lower than
D-AMP concentrations.
Hair analysis
Example chromatograms of chiral analysis for D- and L-AMP are shown in Fig 1, showing
that baseline separation is achieved for the AMP-enantiomers. Results of the chiral LC-MS/MS
analysis of hair samples are given in Table 4. All study completers showed D-AMP positive
hair segments. Participant 13, however, who did not take Elvanse1 on a daily basis, only tested
positive for D-AMP during the third time period (approx. 2.5–4.5 months after the beginning
of the study). L-AMP could be detected in the hair samples of four participants (No. 7, 13, 15,
and 19). For participants 7 and 19, who had self-reported abuse of illegal racemic AMP,
L-AMP concentrations were clearly lower than D-AMP concentrations in all analyzed hair
segments (1.7–6.8 times), suggesting only occasional co-consumption of street AMP. Subjects
13 and 15, however, showed D/L ratios of 0.8–1.4, which strongly indicates that they primarily
consumed racemic street AMP rather than the prescribed dose of Elvanse1.
AMP concentrations measured with the chiral LC-MS/MS method were found to be in
good agreement with those obtained with our routine LC-MS/MS method for achiral determi-
nation of AMP, MAMP, MPH and other basic drugs. For hair samples with total AMP
concentrations� 100 pg/mg (LLOQ of the achiral analysis; n = 55), the results of the chiral
analysis were within 80.9–122.9% (153.3% for one sample) of the results of the achiral analysis.
MAMP could not be detected in any of the collected hair samples indicating that none of
the participants consumed MAMP on a regular basis. Sporadic MAMP consumption cannot
be excluded, but the AMP derived from the metabolism of sporadically consumed MAMP
would not make a significant contribution to the measured AMP hair levels. The self-reported
cocaine use of participant 6 and MDMA use of participant 13 were confirmed through detec-
tion of cocaine and its metabolites (benzoylecgonine, ecgonine methyl ester, cocaethylene,
norcocaine) and MDMA, in all analyzed hair segments. All participants who were prescribed
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Table 3. Results of the urine analysis. D- and L-AMP concentrations are normalized to a creatinine reference concentration of 100 mg/dL.
Participant Sampling time (months)a Elvanse1 (mg/day)b D-AMP (mg/L) L-AMP (mg/L)
1 0 50 7.25 n.d.
2.2 50 1.52 n.d.
4.1 50 3.11 n.d.
2 0 50 12.88 n.d.
1.6 50 7.97 n.d.
4.6 50 2.51 n.d.
3 0 60 21.49 n.d.
2.8 60 10.60 n.d.
4.6 60 8.78 n.d.
4 0 40 7.56 n.d.
2.5 90 6.49 n.d.
5.5 90 4.83 n.d.
5 0 320 12.07 n.d.
2.3 320 8.40 n.d.
4.4 320 5.30 n.d.
6 0 70 5.24 0.43
1.8 70 5.46 n.d.
6.6 70 3.96 n.d.
7 0 30 6.34 0.13
1.8 50 11.21 n.d.
4.7 50 6.64 0.06
8 0 40 8.58 n.d.
5.2 40 1.80 n.d.
7.6 40 3.11 n.d.
9 0 50 0.17 n.d.
2.0 50 1.88 n.d.
4.7 50 1.08 n.d.
10 0 30 2.32 n.d.
2.1 30 3.46 n.d.
4.1 30 3.82 n.d.
11 0 30 2.41 n.d.
3.6 30 2.90 n.d.
6.0 30 1.30 n.d.
12 0 30 3.98 n.d.
2.4 30 2.83 n.d.
3.9 30 0.06 n.d.
13 0 30–50c - f - f
1.9 30–50c n.d. n.d.
4.5 30–50c n.d. n.d.
14 0 30 10.75 n.d.
4.7 40 13.48 n.d.
7.3 70 16.83 n.d.
15 0 60 15.21 n.d.
3.6 60 n.d. n.d.
5.6 60 n.d. n.d.
(Continued)
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MPH as well as seven additional participants showed MPH- positive hair segments (limit of
detection 2 pg/mg), as displayed in Table 4.
D-AMP concentrations in hair segments were highly variable within participants and
between participants receiving the same Elvanse1 dose, as is graphically illustrated in Fig 2.
Participants who were found to consume racemic street AMP or received Elvanse1 in combi-
nation with D-AMP sulfate were not included in Fig 2, since the measured D-AMP concentra-
tions were not solely the result of Elvanse1 intake. For participants, who received a constant
Elvanse1 dose throughout the study, there was a factor of 1.3–9.1 (median 2.2) between the
lowest and the highest D-AMP concentration measured in the three hair segments. Three par-
ticipants underwent dose adjustment during the study. However, only for one of them (Fig 2,
pane at the bottom/right, patient 18), were changes in prescribed dose clearly reflected by the
observed D-AMP concentration changes in the three hair segments.
No correlation between prescribed Elvanse1 dose and D-AMP concentration could be
established among participants. Participants who were prescribed 50 mg/day, for example,
showed hair D-AMP concentrations from 71 to 2000 pg/mg. Furthermore, participant 5, who
was supposed to take 320 mg per day, showed much lower D-AMP concentrations in hair
than did some participants who were prescribed lower doses, e.g. subject 17 (20 / 30 mg),
Table 3. (Continued)
Participant Sampling time (months)a Elvanse1 (mg/day)b D-AMP (mg/L) L-AMP (mg/L)
16 0 50 0.86 n.d.
3.8 50 0.84 n.d.
5.5 50 6.93 n.d.
17 0 20 / 30d 7.72 n.d.
3.4 20 / 30d 4.79 n.d.
5.5 20 / 30d 3.28 n.d.
18 0 30 12.63 n.d.
1.7 60 2.80 n.d.
4.8 60 3.68 n.d.
19 0 100 6.39 n.d.
1.8 100 5.25 n.d.
4.8 100 0.20 n.d.
20 0 50 3.54 n.d.
2.3 50 10.04 n.d.
4.1 50 3.09 n.d.
21 0 100e 17.53 n.d.
2.0 100e 13.78 n.d.
4.4 100e 14.37 n.d.
22 0 80 1.05 n.d.
1.6 80 0.39 n.d.
2.6 80 0.40 n.d.
n.d. not detected
a Time of sample collection after the beginning of the study.
b Prescribed dose of Elvanse1 during the month before sample collection.
c Participant takes variable doses of Elvanse1, but not on a daily basis.
d Participant takes alternating doses of Elvanse1.
e Participant receives Elvanse1 in combination with D-AMP sulfate (5–10 mg/day).
f No urine sample was collected.
https://doi.org/10.1371/journal.pone.0248747.t003
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Table 4. Results of the hair analysis.
Participant Hair color Sampling time (months)a Segment (cm) Elvanse1 (mg/day)b D-AMP (pg/mg) L-AMP (pg/mg) MPH positive
1 blonde 0 2 50 2000 n.d.
2.2 2 50 1218 n.d.
4.1 2 50 1193 n.d.
2 dark blonde 0 2 50 355 n.d.
1.6 2 50 182 n.d.
4.6 2 50 347 n.d.
3 black� 0 14 60 115 n.d. x
2.8 2 60 120 n.d. x
4.6 2 60 < 50 n.d. x
4 brown 0 1 40 96 n.d. x
2.5 2 40 / 90 586 n.d.
5.5 2 90 422 n.d.
5 brown� 0 2 320 360 n.d.
2.3 2 320 232 n.d.
4.4 2 320 223 n.d. x
6 brown-grey 0 2 70 95 n.d. x
1.8 2 70 134 n.d. x
6.6 2 70 118 n.d. x
7 brown 0 2 30 384 121
1.8 2 30 / 50 292 173
4.7 2 50 341 < 50
8 dark blonde� 0 2 40 716 n.d.
5.2 2 40 797 n.d.
7.6 2 40 923 n.d.
9 dark blonde 0 2 50 86 n.d.
2.0 2 50 103 n.d.
4.7 2 50 71 n.d.
10 grey� 0 2 30 111 n.d.
2.1 2 30 235 n.d.
4.1 2 30 60 n.d.
11 black 0 2 30 222 n.d.
3.6 3 30 72 n.d.
6.0 2 30 277 n.d.
12 dark brown 0 2 30 236 n.d. x
2.4 2 30 < 50 n.d. x
3.9 2 30 108 n.d. x
13 dark blonde� 0 2 30–50c n.d. n.d.
1.9 2 30–50c n.d. n.d.
4.5 2 30–50c 142 124 x
14 dark brown 0 2 30 321 n.d.
4.7 2 40 156 n.d.
7.3 2 70 393 n.d.
15 red� 0 2 60 1538 1078
3.6 2 60 1076 1272
5.6 2 60 3209 3763
(Continued)
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subject 8 (40 mg) and subject 1 (50 mg). Even after elimination of those patients, who had
chemically treated hair (marked with an asterisk in Table 4), and additional elimination of
patient 7, for whom additional D/L-Amp uptake was detected in hair, no correlation was
found (Pearson correlation coefficient r = -0.14) between daily Elvanse1 dose (in mg) and
hair D-Amp concentrations (pg/mg).
Discussion
Considering the high clinical and forensic relevance of pharmaco-adherence when treating
individuals with LDX for the neurodevelopmental disorder ADHD, the primary aim of this
study was to evaluate hair analysis for monitoring compliance in patients currently undergoing
long term treatment with Elvanse1, i.e. and to detect possible interruptions of medication
intake or changes in dosage. Since one small previous study reported high inter-individual var-
iations but simultaneously suggested a dose response relationship with a correlation coefficient
of 0.64 between concentration in hair and LDX dosage, we furthermore aimed to gain more
insight into this finding [21]. Additionally, we obtained data on persistence, by evaluating
Table 4. (Continued)
Participant Hair color Sampling time (months)a Segment (cm) Elvanse1 (mg/day)b D-AMP (pg/mg) L-AMP (pg/mg) MPH positive
16 dark blonde� 0 2 50 139 n.d. x
3.8 2 50 67 n.d. x
5.5 2 50 610 n.d. x
17 black� 0 2 20 / 30d 956 n.d. x
3.4 2 20 / 30d 1711 n.d.
5.5 2 20 / 30d 1003 n.d.
18 brown� 0 2 0 / 30 518 n.d. x
1.7 2 30 / 60 1179 n.d. x
4.8 2 60 2866 n.d. x
19 brown-grey 0 2 100 303 n.d.
1.8 2 100 214 <50
4.8 2 100 393 n.d.
20 brown 0 2 50 468 n.d.
2.3 2 50 524 n.d. x
4.1 2 50 2014 n.d. x
21 brown 0 2 100e 291 n.d. x
2.0 2 100e 355 n.d. x
4.4 2 100e 735 n.d.
22 brown 0 2 80 283 n.d.
1.6 2 80 177 n.d.
2.6 2 80 194 n.d.
n.d. not detected
�Cosmetic treatment
a Time of sample collection after the beginning of the study.
b Prescribed dose of Elvanse1 during the time period represented by the hair segment. Slashes indicate that the prescribed Elvanse1 dose changed during the time
period.
c Participant takes variable doses of Elvanse1, but not on a daily basis.
d Participant takes alternating doses of Elvanse1.
e Participant receives Elvanse1 in combination with D-AMP sulfate (5–10 mg/day).
https://doi.org/10.1371/journal.pone.0248747.t004
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treatment continuity to obtain a more thorough understanding of adherence among individu-
als suffering from ADHD and receiving LDX.
We found that individuals undergoing long-term treatment with Elvanse1 were positive
for D-AMP in all urine samples and therapy sessions, except for two patients who did not take
LDX on a daily basis. D-AMP was detected in all hair samples of participants taking prescribed
LDX in dosages between 20 and 320 mg on a daily basis, adding further evidence to the feasi-
bility of chiral LC-MS/MS analysis to confirm LDX use within the approximate period covered
by the hair segment tested.
However, no correlation was found between D-AMP concentrations and prescribed dos-
age, either by analysis of urine taken during the therapy sessions as spot urine samples, with or
without normalization for creatinine, or by analysis of proximal hair segments. The latter
Fig 2. D-AMP concentrations in hair. Bars represent hair segments (assuming an average hair growth of 1 cm/month). Time = 0 corresponds to the time of the
first sample collection. Numbers in bold indicate prescribed Elvanse1 dose, asterisks indicate cosmetic treatment, and dotted lines indicate the limit of
quantification (50 pg/mg).
https://doi.org/10.1371/journal.pone.0248747.g002
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finding contradicts earlier reporting published elsewhere and casts doubt on the current use-
fulness of chiral LC-MS/MS analysis for monitoring treatment compliance beyond a basic esti-
mation of whether or not the drug has been taken regularly over a long period of time. Our
results not only imply that unchanged dosages might lead to a high variance in D-AMP read-
ings but, furthermore, that clinically significant increases in dosage of LDX do not lead to a lin-
ear increase in D-AMP concentrations in proximal hair segments.
Our results are based on a sample that corresponds to clinical reality in a number of vari-
ables, such as co-morbidities, concurrent medication and substance abuse and also common
hair treatment (see Tables 2 and 4). As numerous studies show, up to 80% of individuals with
a diagnosis of adult ADHD suffer from a comorbid psychiatric disorder such as harmful use of
or dependence on psychotropic substances (SUD), affective disorders and/or anxiety disorders
[33–35]. In a clinical setting, SUDs pose a major challenge, both diagnostically and therapeuti-
cally. On the one hand those suffering from ADHD have an increased risk for SUD and, on
the other, 20–30% of individuals who abuse psychoactive substances also suffer from ADHD
[36]. To treat these psychiatric comorbidities, patients with ADHD often receive other medica-
tions in addition to stimulant treatment, on either a short- or long-term basis. In our sample
this concurrent medication predominantly consisted of selective serotonin reuptake inhibitors
(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) for individuals with
co-occurring depressive symptoms or bulimia nervosa. The use of these drugs for the afore-
mentioned disorders is thereby in line with current treatment recommendations [37–39].
In 5 cases (6 cases including non-completers) a dose of more than 70 mg of Elvanse1 was
necessary to achieve a significant symptom reduction. These dosages must be seen against the
background of LDX being a second line treatment for ADHD in Switzerland. As such, the
sample comprised predominantly patients who were MPH non-responders and/or who suf-
fered from MPH side effects. The chronological sequence of a switch from first line MPH to
second line LDX also explains why in some cases MPH was found in addition to LDX in hair
analysis. Furthermore, it should be mentioned that in the case of participant 21, medication
solely with LDX was perceived to be insufficient, resulting in functional impairments at the
workplace, especially in the early morning hours and a combination with D-AMP was initiated
by the treating psychiatrist. This was done to bridge the gap until LDX had reached peak
plasma concentration. Thus, dosages of the medication in this sample are also a reflection of
clinical reality, with sometimes high dosages of LDX and MPH as add-ons.
When non-correlation between dose and concentrations found in urine (or hair) are dis-
cussed, several issues need to be considered, such as daily dose per kg bodyweight, time of
sample collection after dosage, intra- and inter-subject variability in pharmacokinetics and
metabolism, including time to reach steady state concentrations, clearance and dilution of the
urine.
Controlled studies with urinary excretion data, however, are scarce and detailed urine con-
centration-time profiles for LDX and D-AMP have not yet been established. To our knowl-
edge, only two studies have documented AMP concentrations in urine following LDX
administration. Thevis et al. [19] analyzed urine samples obtained from a patient receiving 30
mg of Elvanse1 once daily (corresponding to 17.3 mg of LDX free base) and being at pharma-
cokinetic steady-state; they reported urinary AMP concentrations of 0.04, 0.11, 0.45, and 1.15
mg/L at 3, 6, 9, and 11 h post-administration. Comiran et al. [20] collected urine samples from
six male volunteers 2 h after they had been administered a single oral dose of 70 mg of LDX
dimesylate (corresponding to 40.5 mg of LDX free base). Mean urinary AMP concentration
was 1.51 mg/L (no creatinine-correction in either study). In a study with D-AMP administra-
tion, Poklis et al. [40, 41] determined urinary D-AMP concentrations and also found substan-
tial variability. D-AMP concentrations in six random urine specimens collected over a 3-day
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period from an adult at steady-state receiving 30 mg of D-AMP daily were found to range
from 1.1 to 17.8 mg/L. Healthy male volunteers receiving a single oral dose of 5 mg, 10 mg, or
20 mg of D-AMP displayed a wide range in peak urinary D-AMP concentrations at each dose
and concentration ranges that overlapped considerably following the various doses. These
findings highlight the difficulty of assessing the ingested dose or time since last dose based
upon the drug concentration measured in a single random urine specimen. Since comprehen-
sive studies of urinary elimination are lacking and since urine samples were collected at
unknown time points after LDX intake in the present study, it is difficult to assess whether
the D-AMP concentrations measured herein support daily compliance with the prescribed
Elvanse1 regimen or are the result of non-daily intake.
In addition, it must be kept in mind that the CYP2D6 enzyme which mediates aromatic
hydroxylation of AMP is known to exhibit significant genetic polymorphism, including
marked interethnic variation [42]. However, the lack of correlation between LDX dose and
resultant urinary D-AMP concentrations most likely lies in the fact that the time of urine col-
lection in relation to the last LDX dose was not controlled and was certainly variable. Exact
time intervals between last LDX intake and urine sampling were not recorded in our study.
For hair analysis, time period of dosage as well as variations in hair growth, hair color,
sweat and sebum production, length and thickness of hair, cosmetic hair treatment, hair wash-
ing, etc. are important factors influencing drug concentrations. However, hair analysis has
enjoyed increasing interest as an alternative or complementary matrix to blood and urine in
forensic and clinical drug testing, as it provides a larger window of detection and a long-term
history of drug use. Compared to the analysis of blood and urine, hair testing has further
advantages, such as a reduced risk of sample adulteration, ease of sample collection, transport
and storage, and stability of the incorporated substances [43, 44].
Drug incorporation into hair is recognized to occur via multiple mechanisms and at various
times during the hair growth cycle. Proposed mechanisms include passive diffusion from the
systemic blood circulation to the actively growing follicle, deposition by diffusion from sebum
or sweat into the hair follicle after formation, and external contamination after the hair has
emerged from the skin [45].
Incorporation of drugs from the bloodstream depends on the average concentration in the
blood over time and thus on the ingested dose. Systemic exposure to D-AMP (maximum
plasma concentration [Cmax], area under the plasma concentration-time curve [AUC]) shows
low intrasubject and intersubject variability and appears to be proportional to oral LDX dose,
indicating that there is no enzyme saturation in the conversion of LDX to D-AMP. Further
findings suggest that steady-state D-AMP plasma concentrations are reached after five daily
oral doses of LDX, with no evidence of LDX or D-AMP accumulation. The pharmacokinetics
of LDX and D-AMP did not differ as a function of gender or age when the LDX dose was nor-
malized by body weight [15–17, 46–49]. With passive diffusion, it would be expected that a
correlation between hair concentration and steady-state D-AMP plasma concentration, and
thus ingested LDX dose, can be established for compliant patients.
However, physicochemical properties of drugs (melanin affinity, lipophilicity, and basicity)
are a more important factor for incorporation from blood into hair than plasma concentra-
tions. It is well documented that hair pigmentation (melanin content) is an important factor
influencing the incorporation of basic drugs such as AMP into hair, which may lead to a so-
called color bias. Dark-haired persons (higher melanin concentrations) were found to have
much higher concentrations of basic drugs than subjects with lighter hair when exposed to the
same dose [50–53].
The participants in the present study had different natural hair colors, and nine of them
reported using cosmetic hair treatments (mostly dyeing, but also bleaching and thermal
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straightening) as indicated in Table 3. Cosmetic treatments were found to decrease the con-
centrations of AMP in hair [54–56]. This as well as the possibility of color bias need to be kept
in mind when interpreting the hair results.
Only few comparisons could be drawn between participants having cosmetically untreated
hair and receiving the same Elvanse1 dose. Blonde-haired participant 1 had higher mean hair
D-AMP concentrations than brown-haired participant 20, which contradicts expectations
based on the melanin-dependent incorporation of basic drugs. Participants 2 and 9, however,
both having dark blonde hair and receiving an Elvanse1 dose of 50 mg/day, had lower mean
hair D-AMP concentrations than brown-haired participant 20 (294 pg/mg and 87 pg/mg,
respectively, versus 1002 pg/mg). Participants 11 and 12, who both received a daily Elvanse1
dose of 30 mg and had dark hair (black and dark brown, respectively) had similar D-AMP con-
centrations in their hair.
When interpreting the hair D-AMP concentrations measured in the present study, the pos-
sible contribution of incorporation mechanisms other than diffusion from blood must also be
considered (diffusion from sebum/sweat and external contamination). Numerous studies have
demonstrated the detection of drugs and their metabolites in sweat/sebum, including AMP
and MPH [57]. Individual variability in sweat and sebum secretion could contribute to the
observed variability in hair D-AMP concentration in subjects receiving the same Elvanse1
dose.
From a clinical perspective adherence (a combination of persistence and compliance) to
therapy is an important predictor for treatment outcome and may be problematic for patients
with mental health issues in general, but especially for patients with attention deficit hyperac-
tivity disorder due to symptoms such as concentration problems, inattention and disorganiza-
tion, which might lead to an “unintentional nonadherence” [58]. A more recent review by
Adler and Nierenberg reported that nonadherence and medication discontinuity increases
when patients are followed for longer periods of time and found mean continuities of usually
less than 6 months [4]. It also revealed that most of the studies on this topic address the issue
in children but not in adults, despite the fact that ADHD persists well into adulthood. The
authors raise the question of whether monitoring pharmacotherapy could influence adherence
and if so, in what way. Interestingly, the rates of interruption of medication were lower for
long-acting preparations compared to those for immediate release formulations. This result
underlines the fact that patients with ADHD do not use the prescribed drugs primarily for rec-
reational purposes, i.e. they do not want to achieve a "flash" although some misuse has been
described among diagnosed adolescents taking prescription stimulants [59]. Our findings con-
cerning LDX as the formulation with the longest duration of efficacy among the currently
available drugs for ADHD are in alignment with this data. While our study only investigated
adherence to LDX and did not directly compare subjects prescribed short-acting ADHD medi-
cation, our results indicated that in the LDX group of 24 patients, 18 patients (75%) showed
good compliance and persistence with the medication over the monitored time-period, with
only two patients withdrawing from the study. These numbers are significantly higher than
the numbers reported by Adler and Nierenberg for short-acting preparations, where 13.2% to
64% discontinued their treatment. Moreover, in comparison to other medications used in psy-
chiatry, e.g. antidepressants, we can report good adherence to treatment with LDX in our sam-
ple of adults with ADHD. For example, Sawada et al. investigated persistence and compliance
with antidepressant treatment among individuals with depression and found that only 44.3%
continued antidepressant treatment for 6 months. Furthermore, 63.1% of patients discontinu-
ing their initial antidepressant, did so without consulting their treating physician [60, 61].
From a forensic point of view, the results of the present study have significant implications
for the assessment of treatment adherence in a medico-legal context. To exemplify, these
PLOS ONE Hair analysis in monitoring the compliance of ADHD patients under treatment with Lisdexamphetamine
PLOS ONE | https://doi.org/10.1371/journal.pone.0248747 March 30, 2021 17 / 24
implications will be discussed in the areas of criminal law, social law and traffic law in the
Swiss juridical system. In criminal law, in particular, release from therapeutic measures
according to the Swiss Criminal Code (SCC) is linked to a reduced risk of reoffending [62, 63].
Therapy adherence is considered an important variable during risk assessment [64, 65].
If, as suggested by other authors, results are interpreted quantitatively with a given coeffi-
cient linking dose and response by legal authorities, those affected could be suspected of not
following treatment protocol with regards to prescribed medication, despite regularly taking a
constant dose and being persistent and compliant. A lack of adherence to therapy, on the
other hand, has a negative effect on the assessment of the prognosis for relapse and can thus
unjustifiably prolong the duration of court mandated treatment and represent an obstacle to
successful rehabilitation [66].
Since the prescription of LDX (or other stimulants for that matter) to individuals in deten-
tion who suffer from ADHD is an exception, decreasing readings of AMP despite stable doses
in the hair, could, if interpreted quantitatively, suggest deviation and misuse of LDX by those
individuals, which might lead to dire, albeit unwarranted, consequences [67–70]. Prescriptions
for stimulants are often not filled because it is assumed by prison authorities that the substance
will be “smuggled” to other inmates; thus such an interpretation has consequences not only for
the patients themselves, but possibly also for other detainees suffering from this highly preva-
lent disorder who are in need for treatment [71–73]. On a related note, it should be added that
positive AMP findings in urine and hair may not only be the consequence of the misuse of an
illegal substance, but also the consequence of taking another prescribed drug such as famprofa-
zone, a nonsteroidal anti-inflammatory agent (NSAID). If the results of hair analysis are not
interpreted carefully, an individual in custody may thus be subject to unjustified sanctions,
including confinement [74].
In social law, on the other hand, the distribution of benefits, either in the form of disability
pensions or professional reintegration efforts, are also determined by adherence to therapy.
There is a so-called “obligation to cooperate” that is designed to minimize the financial conse-
quences for society of sustained disability [75, 76]. Here, too, those affected may suffer consid-
erable disadvantage if, based on forensic experts’ testimony, legal authorities interpret the
results of hair-analysis for LDX quantitatively. It is conceivable, for example, that vocational
training will not be financed or initiated, as it is assumed that the individual concerned does
not show therapy-adherent behavior.
Mobility and possession of a valid driver’s license are prerequisite for employment in many
professional constellations, and access to an automobile increases not only the chances of
being employed but influences the quality of employment, as measured by earnings [77, 78].
If, in the context of police traffic stops or traffic medical examinations, conclusions about ille-
gal drug use and treatment compliance are drawn without acknowledging the limitations of
chiral LC-MS/MS hair analysis, the results can lead to a massive burden for the individual,
both professionally and socially [79, 80].
Nevertheless, if the data are carefully interpreted and limitations are openly communicated
to legal authorities, chiral hair analysis for D-AMP and L-AMP can represent an instrumental
enrichment for both forensic and general psychiatrists, since confirming LDX use within the
approximate period covered by the hair segment tested, can be one (further) objective element
when assessing therapy adherence.
Limitations
A major concern of the study participants was that too much hair would be collected and that
hair sampling would negatively impact their hair cut and leave visible bald spots on their scalp.
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Therefore, only one lock of hair was taken at each time point and only as much hair as neces-
sary for the analysis was cut, although the homogeneity from thicker hair-locks was arguably
better.
The question of the representativity of a single hair-lock for drug analysis was addressed by
studies of Dussy et al. [81] and Meier et al. [82]. Dussy et al. [81] showed that incorporation of
substances into head hair is not necessarily uniform and that significant differences in analyte
concentrations may be found in hair-locks sampled from the same person covering the same
time period, depending on the sampling site on the head. A limitation of the hair analysis here
is that, due to the aforementioned objection (visibility of bald spots), only one hair sample was
taken and analyzed at each time point.
Furthermore, interpretation of segmental hair analysis results is restricted by experimental
as well as biological sources of inaccuracy. Experimental errors can occur during fixing and
cutting a hair-lock from the scalp prior to segmentation. In routine samples, this can lead to a
mutual shift of single hair-strands by up to 5 mm corresponding to a time error of about two
weeks. However, great care was taken to avoid such errors in the present study.
Conclusions
In light of the negative consequences associated with intentional or unintentional non adher-
ence to stimulant treatment for individuals with ADHD [58, 59], chiral LC-MS/MS hair analysis
for patients receiving LDX might be a practical non-invasive way to confirm LDX use within
the approximate period covered by the hair segment tested. However, currently hair analysis
cannot be used in "compliance monitoring" where "compliance" means appraising whether an
individual is taking doses according to the prescription issued. It does not provide information
on dose or frequency of LDX use. This might be due to the interindividual variability of concen-
trations in hair produced by factors such as hair pigmentation and cosmetic hair treatments,
but also diffusion from sweat and external contamination. Hair drug concentrations at different
stages of a long-term treatment should thus be interpreted with caution by forensic and legal
experts alike when making assessments of treatment adherence, since unchanged dosages of
LDX might not only lead to a high variance in hair drug concentration, but also to conditions
where clinically significant increases in dosage of LDX might not be reflected at all.
Forensic experts advising courts and/or other legal entities should furthermore keep in
mind that AMP in urine or hair may not only be the result of methamphetamine abuse, but
also a consequence of the intake of prescription or over the counter medications such as selegi-
line, which is used in the treatment of Parkinson’s disease and major depressive disorder, or
famprofazone, a NSAID. On a more positive note, we can conclude that the detection and/or
differentiation of co-consumption of illegal D,L-AMP and other drugs was successful. This
aspect, in turn, could make it possible to closely monitor misuse among individuals receiving
LDX, especially in areas where, from a forensic point of view, concomitant use of other drugs
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